Regeneron Pharmaceuticals (STU:RGO) Cash Flow for Dividends: €-322 Mil (TTM As of Mar. 2026)


STU:RGO Regeneron Pharmaceuticals Inc STU:RGO
87 GF Score
Price €551.80
GF Value €785.39
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Cash Flow for Dividends?

Regeneron Pharmaceuticals STU:RGO -0.50% 87 Cash Flow for Dividends is €-322 Mil as of Mar. 2026. GuruFocus rates STU:RGO with a GF Score™ of 87/100 and a GF Value™ of €785.39 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Regeneron Pharmaceuticals's cash flow for dividends for the three months ended in Mar. 2026 was €-85 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was €-322 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Regeneron Pharmaceuticals's quarterly payment of dividends increased from Sep. 2025 (€-78 Mil) to Dec. 2025 (€-79 Mil) and increased from Dec. 2025 (€-79 Mil) to Mar. 2026 (€-85 Mil).

Regeneron Pharmaceuticals's annual payment of dividends stayed the same from Dec. 2023 (€0 Mil) to Dec. 2024 (€0 Mil) but then increased from Dec. 2024 (€0 Mil) to Dec. 2025 (€-316 Mil).

Regeneron Pharmaceuticals Cash Flow for Dividends Related Terms

Regeneron Pharmaceuticals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Cash Flow for Dividends Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -316.24

Regeneron Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -86.77 -80.28 -77.70 -79.17 -84.60
STU:RGO
87GF Score
Regeneron Pharmaceuticals Inc STU:RGO
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-322 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €-322 Mil mean?
Regeneron Pharmaceuticals (STU:RGO) has a Cash Flow for Dividends of €-322 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Cash Flow for Dividends too high?
Regeneron Pharmaceuticals' current Cash Flow for Dividends is €-322 Mil. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Cash Flow for Dividends compare to ALNY and RVMD?
Regeneron Pharmaceuticals' Cash Flow for Dividends of €-322 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Cash Flow for Dividends is €-322 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Significantly Undervalued. The stock's GF Value™ is €785.39, compared to a current price of €551.80 — trading 29.7% below its estimated fair value. The current Cash Flow for Dividends is €-322 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Cash Flow for Dividends is €-322 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €551.80 is trading 29.7% below its estimated GF Value™ of €785.39. GuruFocus considers Regeneron Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for STU:RGO:

  • Cash Flow for Dividends: €-322 Mil
  • GF Value™: €785.39 vs. price of €551.80 (29.7% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score

Get the complete analysis for STU:RGO

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€551.80
Price
€785.39
GF Value